Atriva Therapeutics

@AtrivaTx

Clinical stage biopharmaceutical company developing host-targeting inhibitors against respiratory viral infections.

Tübingen, Germany
Vrijeme pridruživanja: listopad 2019.

Medijski sadržaj

  1. prije 3 sata

    ausbremsen! Medikamentös gegen ! Atriva in diesem Artikel aus vorgestellt the ! Medication against !

  2. 3. velj

    Knowledge and science have no borders. Scientists and experts of all World are working together to find a solution to beat . German scientists are also contributing by working and sharing results.

  3. 29. sij

    The world is under virus attack, but German scientists are already on the move. spoke with Prof. Dr. Ludwig, developer of ’ host-targeting candidate, , about pandemic threats like , SARS, MERS and .

  4. 15. sij

    The 3rd and last conference during the ’s San Francisco tour is the 15th Non-Dilutive Funding Summit . Meet our representatives to learn more about our potential in the development of host-targeting therapies.

  5. 14. sij

    We look forward to telling you more about , our host-targeting approach to treat , at the RESI conference, where 500+ early stage investors gather every year. Dr. Rainer Lichtenberger will present Atriva during the track 4, 8:00 am.

  6. 13. sij

    Learn more about ’s host-targeting therapy candidate against , hanta and further severe respiratory viral infections at the company presentation of our CEO, Dr. Lichtenberger, today at . Join us at 11:30, Franciscan D.

  7. 9. sij

    kicks off the new year by travelling to to participate in three conferences. Dr. Lichtenberger, CEO, Dr. Wallasch, COO, and Dr. Björn Cochlovius, VP BD, will represent the Company and be available for networking and one-on-ones.

  8. 20. pro 2019.

    is always lurking, especially during the winter season, which impairs our immune system. At , we are developing a unique portfolio of broadly active and efficacious antiviral drugs. Stay warm and enjoy the . and from Atriva.

  9. 19. pro 2019.

    ! ’s co-founder and scientific advisor Prof. Ludwig, head of the Virology Institute at is prominently featured in an interesting article on the by : .

  10. 15. pro 2019.

    reports the weekly status of Germany’s incidence. As every year, the maximum is expected in February. ’s is developing to reduce the occurrence of and flu-like-illness by inhibiting the virus’ replication machinery independently of the strain.

  11. 20. stu 2019.

    ’s strategy and product candidate “may revolutionize treatment of and other severe respiratory viral infections” and be “a quantum leap in respiratory therapies”. Learn more in the article by

  12. 11. stu 2019.

    Learn more about against and respiratory in the presentation of Dr. Rainer Lichtenberger, our CEO, today at 5.45 PM during the “Infectious Disease Company Presentations” section Level 1/Hall B1/Room 7

  13. 8. stu 2019.

    announces the successful conclusion of the Ph. I trial for in . Dr. Lichtenberger, CEO: “An important milestone towards a novel flu drug against this public health danger and its threat of a new

  14. 4. stu 2019.

    On Nov 11 , EU's largest life science partnering conference, starts in . Our CEO Dr. Lichtenberger is happy to discuss our lead product against , and other severe respiratory infections. Use to set up a meeting!

  15. 1. stu 2019.

    Let’s go by spreading awareness - today is ! Atriva commits to with our first-in-class host-targeting MEK inhibitor . We address the need for a novel, broadly active, resistance-avoiding therapy and for a prolonged treatment window.

  16. 20. lis 2019.

    Atriva Theraputics is now also on Twitter! We can’t wait to tell you more about our lead product , a clinical- stage, first-in-class host-targeting agent that inhibits viral replication in and other respiratory infections. Stay tuned!

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·